# Study of Paclitaxel in Patients With Ovarian Cancer

> **NCT00989131** · PHASE3 · COMPLETED · sponsor: **Oasmia Pharmaceutical AB** · enrollment: 789 (actual)

## Conditions studied

- Epithelial Ovarian Cancer
- Primary Peritoneal Cancer
- Fallopian Tube Cancer

## Interventions

- **DRUG:** Paclical®
- **DRUG:** Taxol®

## Key facts

- **NCT ID:** NCT00989131
- **Lead sponsor:** Oasmia Pharmaceutical AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 789 (ACTUAL)
- **Last updated:** 2014-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00989131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00989131, "Study of Paclitaxel in Patients With Ovarian Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00989131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*